Skip to main content

Short-Term Incentive

Citing Forbes contributor Jim Golden's take on genomics in clinical oncology, Mike the Mad Biologist says microbial genomics will become more profitable than human genomics over the short term. "Microbial genomes are cheap, fast, and you can provide epidemiological relevant information to clinical laboratories, hospital networks, and public health departments," Mike says, later adding, "in two or three years, I don't see any technical hurdles to routine microbiological surveillance in hospitals." By comparison, human genomes are costly, take considerably longer, and do not necessarily yield clinically actionable information, Mike notes.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.